Convalescent serum lines up as first-choice treatment for coronavirus

Nat Biotechnol. 2020 Jun;38(6):655-658. doi: 10.1038/d41587-020-00011-1.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use
  • Betacoronavirus / immunology*
  • COVID-19
  • COVID-19 Serotherapy
  • Clinical Trials as Topic
  • Coronavirus Infections* / immunology
  • Coronavirus Infections* / therapy
  • Humans
  • Immune Sera / immunology
  • Immunization, Passive
  • Pandemics*
  • Pneumonia, Viral* / immunology
  • Pneumonia, Viral* / therapy
  • Recombinant Proteins / immunology
  • Recombinant Proteins / therapeutic use
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Immune Sera
  • Recombinant Proteins